Objective To summarize the visual outcome of patients with severe ocular trauma treated with vitreous surgery. Methods Clinical data of 188(191 eyes) with severe ocular trauma treated with vitreous surgery in a period from November 1996 to April 1998 were analysed retrospectively. Results The study included penetrating injury in 56 eyes, foreign bodies in the posterior segment in 70 eyes, blunt injury in 41 eyes , and globe rupture in 24 eyes. Main complications included endophthalmitis in 35 eyes, choroidal bleeding in 20 eyes, retinal detachment in 60 eyes, and vitreous hemorrhage in 97 eyes. Post-opera-tively, out of 188 eyes, except for 3 of patients too young to examine, visual acuity improved in 133(70.7%), including 85(45.2%) with visal acuity 0.02-1.0, 46(24.5%) remained unchanged; and 9(4.8%) had worse vision. Among 34 with no-light-perception, 12 had light-perception or over. Conclusion A majority of severe trauma eyes can be salvaged with considerable visual recovery after adequate and timely vitreous surgery. (Chin J Ocul Fundus Dis,1999,15:4-6)
Objective To systematically evaluate the effectiveness of somatostatin analogs versus placebo for Graves’ ophthalmopathy (GO). Methods Such databases as PubMed, EMbase, The Cochrane Library, WanFang Data, CNKI, VIP and CBM were searched to collect the randomized controlled trails (RCTs) about somatostatin analogs for Graves’ Ophthalmopathy (GO) pulished by March 2012, while the bibliographies of the included literatue were also retrieved. According to the inclusion criteria, two reviewers screened literature, extracted data and assessed the quality of the included studies. Then meta-analysis was conducted using RevMan 5.0 software. Results A total of 5 RCTs involving 210 patients were included. The results of meta-analysis showed that somatostatin analogs could reduce the clinical activity score (CAS) of GO patients (MD=0.58, 95%CI 0.02 to1.13, P=0.04), but the effects in reducing the degree of proptosis (mm) was still unverifiable (MD=0.21, 95%CI –0.14 to 0.56, P=0.24). It did not show obvious effects for diplopia, orbital volume, intraocular pressure, visual acuity or the restriction of eye movements. The existing evidence could not confirm that somatostatin analogs were effective for GO (OR=1.32, 95%CI 0.45 to 3.9, P=0.61). Conclusion Somatostatin analogs can reduce the CAS of GO patients, but without significantly clinical significance. Moreover, the effect of reducing proptosis is sitll unverifiable. So the existing evidence cannot confirm that somatostatin analogs are effective for GO. For the quality and quantity limitation of the included studies, this conclusion needs to be proved by performing more high quality RCTs.
Objective To evaluate the diagnostic accuracy of enzyme immunoassay (EIA) for chlamydia trachomatis (CT). Methods The diagnosis trials on EIA for CT were searched in the databases such as PubMed (1966 to Dec. 2011), The Cochrane Library (Issue 12, 2011), EMbase (1974 to Dec. 2011), CNKI (1994 to Dec. 2011), VIP (1989 to Dec. 2011) and CBM (1978 to Dec. 2011), meanwhile the manual and other retrieves were also conducted. Two reviewers evaluated the quality of the included trials according to the quality assessment of diagnostic accuracy studies (QUADAS), and then meta-analysis was performed using Meta Analyst and RevMan 5.0 software. Results A total of 17 trials involving 9 461 participants were included. The results of meta-analysis showed that the weighted sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the area under SROC curve were 0.847 (95%CI 0.571 to 0.995), 0.964 (95%CI 0.890 to 0.994), 25.972 (95%CI 18.587 to 36.293), 0.156 (95%CI 0.114 to 0.212), 228.875 (95%CI 127.136 to 412.028), and 0.953, respectively. Conclusion EIA for CT has higher sensitivity and specificity, so EIA is recommended for preliminary screening CT and diagnosing the highly suspected cases or the patients without obvious signs and symptoms.
Objectives To assess the clinical effectiveness of non-penetrating trabecular surgery versus trabeculectomy for open angle glaucoma. Methods We searched the Cochrane Central Register of Controlled Trials (issue 2, 2007), MEDLINE (1966 to May 2008), EMbase (1980 to May 2008), and CMB-disk (1979 to May 2008). We also hand searched relevant journals and conference proceedings. Data were extracted by two reviewers independently using an extraction form. The Cochrane Collaboration’s RevMan 5.0 software was used for statistical analysis. Results Three RCTs involving 127 participants (144 eyes) with previously untreated open angle glaucoma were included. Meta-analysis showed that compared with non-penetrating trabecular surgery, trabeculectomy increased the proportion of patients with reduced postoperative intraocular pressure (WMD2.78, 95%CI 1.41 to 4.15), improved the operation success rate (RR 0.53, 95%CI 0.37 to 0.77), and reduced the use of postoperative antiglaucoma medication (WMD 0.96, 95%CI 0.84 to 1.08). Non-penetrating trabecular surgery reduced the incidence of postoperative complications (RR 17.00, 95%CI 8.36 to 26.00). Conclusion Since the sample sizes of the included trials are relatively small, and the two procedures are also related to progressive visual field loss and optic disk damage, more well-designed large-scale RCTs are required.
Objective To evaluate the effect of epristeride on gross hematuria secondary to transurethral resection of prostate (TURP). Methods A total of 50 patients with gross hematuria secondary to TURP were divided into two groups: 25 patients were treated with routine treatment plus 5 mg epristeride, twice a day for 3 months, while the other 25 only received routine treatment. Results At the 6-month follow-up visit, gross hematuria recurred in 63% of patients in the control group, but in only 30% of patients in the epristeride group. The difference was statistically significant (Plt;0.05). Moreover, the grade of gross hematuria was significantly lower in the epristeride group (Plt;0.05). Conclusion Epristeride appears to be effective in treating gross hematuria secondary to TURP.
目的 探讨碘131（131I）治疗后Graves眼病（GO）预后与血清促甲状腺激素受体抗体（TRAb）水平变化之间的关系。 方法 选择2011年5月－12月初发Graves病患者238例，分为GO组124 例和非GO组114 例，分别检测131I治疗前及131I治疗后2、3、6个月甲状腺功能和TRAb，GO患者131I治疗前和治疗后6 个月进行临床活动度评分（CAS）。 结果 131I治疗前各组TRAb水平差异无统计学意义（P＞0.05），TRAb水平与GO CAS评分之间无相关；131I治疗后6个月所有患者TRAb水平显著增加；非GO组有5例新发GO，新发GO组与其他患者的TRAb水平分别为（58.7 ± 77.9）、（61.9 ± 81.1）U/L，差异无统计学意义（P＞0.05）；GO组又分为GO无变化29例，GO加重17例，GO缓解78例，三组患者TRAb水平分别为（53.5 ± 77.6）、（66.2 ± 89.9）、（66.8 ± 42.2）U/L，差异无统计学意义（P＞0.05）。 结论 131I治疗后患者TRAb水平显著增加，但TRAb水平的变化和GO预后无关，TRAb与GO的关系还需要进一步研究。
目的 对比A型超声角膜测厚仪、OrbscanⅡ眼前节分析仪和Pentacam眼前节分析仪测量准分子激光原位角膜磨镶术（LASIK）前后中央角膜厚度的差异。 方法 2010年10月－2011年3月，分别使用A型超声角膜测厚仪、OrbscanⅡ和Pentacam眼前节分析仪测量137例（274只眼）近视患者LASIK前后中央角膜厚度，并对测量结果进行配对t检验和Pearson相关性分析。 结果 LASIK术前A型超声、OrbscanⅡ和Pentacam测量值分别为（526.6 ± 34.1）、（516.6 ± 34.2）、（539.8 ± 31.5） μm，Pentacam测量值较A型超声和OrbscanⅡ测量值高，差异有统计学意义（P＜0.05），而A型超声和OrbscanⅡ测量值之间差异无统计学意义（P＞0.05）；LASIK术后6个月A型超声、OrbscanⅡ和Pentacam测量值分别为（448.2 ± 48.5）、（391.9 ± 58.5）、（451.5 ± 46.4） μm，LASIK术后A型超声和Pentacam测量值无差异（P＞0.05），而OrbscanⅡ测量值较A型超声和Pentacam低；Pearson相关分析显示，LASIK术后Pentacam和A型超声CCT测量值呈高度相关（P＜0.05）。 结论 3种仪器的中央角膜厚度测量值不可互换，LASIK术后A型超声和Pentacam量值较为准确。Objective To compare the difference in measurements of central corneal thickness (CCT) using A-scan, OrbscanⅡand Pentacam before and after laser in situ keratomileusis (LASIK). Methods Between October 2010 and March 2011, the CCT of 137 patients (274 eyes) were measured by A-scan, OrbscanⅡ and Pentacam, and the results were analyzed by paired t-tests and Pearson correlation. Results Before LASIK, the values of CCT measured by A-scan, OrbscanⅡ and Pentacam were (526.6 ± 34.1), (516.6 ± 34.2), and (539.8 ± 31.5) μm respectively; paired t-tests showed the CCT values obtained with Pentacam were significantly higher than those with other methods (P＜0.05), but there were no statistical significant differences between OrbscanⅡand Pentacam measurements (P＞0.05). Six months after LASIK, the values of CCT measured by A-scan, OrbscanⅡand Pentacam was (448.2 ± 48.5), (391.9 ± 58.5), and (451.5 ± 46.4) μm respectively; the CCT values obtained with A-scan and Pentacam didn’t differ much from each other (P＞0.05), and the CCT values obtained with OrbscanⅡwere lower than those obtained with A-scan and Pentacam. There was a high correlation between A-scan and Pentacam measurements. Conclusion The these methods measuring CCT could not be used interchangeably, and A-scan and Pentacam after LASIK were more precise than OrbscanⅡ.
目的 比较单纯手法复位和手法复位合并口服抗眩晕药治疗良性阵发性位置性眩晕（BPPV）的短期和长期疗效。 方法 将2004年1月－2011年6月期间收治的236例BPPV患者随机分为两组，对照组112例采用单纯手法复位，观察组124例在手法复位基础上配合口服抗眩晕药治疗，两组均于1周和3个月后复查，并随访观察1年，且比较其疗效。 结果 观察随访1年后，对照组总治愈率92.86% (104/112），观察组治愈率为93.54%（116/124），两者比较差异无统计学意义。 结论 单纯手法复位和手法复位合并口服抗眩晕药治疗BPPV其疗效相当，但可作为BPPV患者的首选治疗方法。Objective To evaluate the short-term and long-term effect of canalith repositioning procedures with or without anti-vertigo drugs on benign paroxysmal positional vertigo (BPPV). Methods A total of 236 cases of BPPV that were treated with particle repositioning maneuver with medicine treatment from January 2004 to June 2011. The patients were divided into control group (112 patients, underwent canalith repositioning procedures) and observation group (124 patients, underwent canalith repositioning procedures with medication of anti-vertigo drugs). The two groups were reappraised after one week and three months respectively, and the follow-up duration was one year. Results The success rate was 92.86% (104/112) in the control group and 93.55%(116/124) in the observation group one year after the treatment. The difference between the two groups was not significant. Conclusion The effect of canalith repositioning procedures with or without anti-vertigo drugs on BPPV does not differ much from each other.